Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem HDT in High Risk Aggressive NHL
NCT00869284Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Oct 1994
- Primary completion
- Jul 1999
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, epirubicin, vindesine, prednisone, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in non-Hodgkin lymphoma (NHL), sponsored by French Innovative Leukemia Organisation. Started Oct 1994; status: completed.
02
Drugs
cyclophosphamideepirubicinvindesineprednisonemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00869284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869284.